A representative from the Drug Enforcement Administration (DEA) has expressed the agency’s intention to dispel any misunderstandings surrounding its drug scheduling review process, emphasizing a commitment to transparency. The DEA is currently in the process of potentially reclassifying marijuana and aims to ensure clarity in its decision-making.